CN1898563B - 诊断乳腺癌的方法 - Google Patents

诊断乳腺癌的方法 Download PDF

Info

Publication number
CN1898563B
CN1898563B CN2004800347098A CN200480034709A CN1898563B CN 1898563 B CN1898563 B CN 1898563B CN 2004800347098 A CN2004800347098 A CN 2004800347098A CN 200480034709 A CN200480034709 A CN 200480034709A CN 1898563 B CN1898563 B CN 1898563B
Authority
CN
China
Prior art keywords
cells
brc
breast cancer
expression
leu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2004800347098A
Other languages
English (en)
Chinese (zh)
Other versions
CN1898563A (zh
Inventor
中村佑辅
片桐丰雅
中鹤修一
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oncotherapy Science Inc
Original Assignee
Oncotherapy Science Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncotherapy Science Inc filed Critical Oncotherapy Science Inc
Publication of CN1898563A publication Critical patent/CN1898563A/zh
Application granted granted Critical
Publication of CN1898563B publication Critical patent/CN1898563B/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57515—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the breast
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hospice & Palliative Care (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CN2004800347098A 2003-09-24 2004-08-10 诊断乳腺癌的方法 Expired - Fee Related CN1898563B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US50557103P 2003-09-24 2003-09-24
US60/505,571 2003-09-24
PCT/JP2004/011741 WO2005029067A2 (en) 2003-09-24 2004-08-10 Method of diagnosing breast cancer

Publications (2)

Publication Number Publication Date
CN1898563A CN1898563A (zh) 2007-01-17
CN1898563B true CN1898563B (zh) 2011-11-23

Family

ID=34375580

Family Applications (2)

Application Number Title Priority Date Filing Date
CN2004800347098A Expired - Fee Related CN1898563B (zh) 2003-09-24 2004-08-10 诊断乳腺癌的方法
CN2004800347011A Expired - Fee Related CN1890381B (zh) 2003-09-24 2004-09-24 诊断乳腺癌的方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN2004800347011A Expired - Fee Related CN1890381B (zh) 2003-09-24 2004-09-24 诊断乳腺癌的方法

Country Status (9)

Country Link
US (3) US7531300B2 (enExample)
EP (2) EP1668354A2 (enExample)
JP (3) JP4579246B2 (enExample)
CN (2) CN1898563B (enExample)
AT (1) ATE508202T1 (enExample)
DE (1) DE602004032556D1 (enExample)
ES (1) ES2365732T3 (enExample)
TW (2) TW200512298A (enExample)
WO (2) WO2005029067A2 (enExample)

Families Citing this family (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ547955A (en) * 2003-12-05 2010-03-26 Erasmus Mc Predicting response and outcome of metastatic breast cancer anti-estrogen therapy
FR2875512B1 (fr) * 2004-09-17 2011-02-04 Diagnogene S A Biopuce de diagnostic du caractere metastatique ou localise d'une tumeur mammaire, procede et kit d'utilisation
WO2006093337A1 (ja) * 2005-03-03 2006-09-08 Takeda Pharmaceutical Company Limited 癌の予防・治療剤
ES2348161T3 (es) * 2005-03-11 2010-11-30 Oncotherapy Science, Inc. Métodos para dañar células usando funciones efectoras de anticuerpos anti-gfra1.
WO2007013359A2 (en) * 2005-07-28 2007-02-01 Oncotherapy Science, Inc. Cancer related gene rasgef1a
EP1910570B1 (en) 2005-07-29 2011-04-13 Oncotherapy Science, Inc. Gene and polypeptide relating to breast cancer
JP2007037421A (ja) * 2005-08-01 2007-02-15 Osaka Univ 大腸癌リンパ節転移の有無を予測するための遺伝子セット
US7662580B2 (en) 2005-11-10 2010-02-16 Aurelium Biopharma Inc. Tissue diagnostics for breast cancer
US20110087436A1 (en) * 2005-11-17 2011-04-14 Maria Klapa Method and system for analysis of time-series molecular quantities
EP1983046A4 (en) * 2006-02-03 2009-03-25 Messengerscape Co Ltd GENERAL GROUP APPLICABLE TO CANCER PROSTICE
US8138167B2 (en) 2006-02-10 2012-03-20 Oncotherapy Science, Inc. Methods for treating lung cancers
US20080108065A1 (en) * 2006-04-28 2008-05-08 Indra Poola Systems and diagnostic methods for breast cancer using mmp-1 markers
JP5339291B2 (ja) * 2006-08-10 2013-11-13 オンコセラピー・サイエンス株式会社 乳癌に関連する遺伝子およびポリペプチド
EP3135773A1 (en) * 2006-09-27 2017-03-01 Sividon Diagnostics GmbH Methods for breast cancer prognosis
WO2008093427A1 (ja) * 2007-02-01 2008-08-07 Oriental Yeast Co., Ltd. 乳癌細胞の検出方法
US8105796B2 (en) 2007-02-15 2012-01-31 Universita' Degli Studi Di Torino Regulation of expression of PI3Kβ protein in tumors
TW200908998A (en) * 2007-06-27 2009-03-01 Oncotherapy Science Inc Compositions and methods of treating cancer
KR101543624B1 (ko) 2007-08-20 2015-08-11 온코세라피 사이언스 가부시키가이샤 Ｆｏｘｍ１ 펩티드 및 이를 포함하는 약학적 조성물
ES2537323T3 (es) 2007-08-20 2015-06-05 Oncotherapy Science, Inc. Péptido CDCA1 y agente farmacéutico que lo comprende
US8486903B2 (en) * 2007-10-04 2013-07-16 Agency For Science, Technology And Research (A*Star) TAZ/WWTR1 for diagnosis and treatment of cancer
US8088715B2 (en) * 2007-11-13 2012-01-03 Ikonisys, Inc. Detection of circulating tumor cells in peripheral blood with an automated scanning fluorescence microscope
WO2009089548A2 (en) * 2008-01-11 2009-07-16 H. Lee Moffitt Cancer & Research Institute, Inc. Malignancy-risk signature from histologically normal breast tissue
WO2009116860A1 (en) * 2008-03-17 2009-09-24 Vereniging Het Nederlands Kanker Instituut Markers providing prognosis of metastasis among cancer patients
TWI526219B (zh) 2008-06-19 2016-03-21 腫瘤療法 科學股份有限公司 Ｃｄｃａ１抗原決定位胜肽及含此胜肽的疫苗
TW201008574A (en) 2008-08-19 2010-03-01 Oncotherapy Science Inc INHBB epitope peptides and vaccines containing the same
US20100055705A1 (en) * 2008-08-29 2010-03-04 Wilson Gerald M Compositions and methods for diagnosing and treating cancer
TWI469791B (zh) 2009-02-18 2015-01-21 Oncotherapy Science Inc Ｆｏｘｍ１胜肽以及含此胜肽之疫苗
KR101174369B1 (ko) 2009-05-01 2012-08-16 한국생명공학연구원 유방암 진단용 바이오마커 및 유방암 진단제
US20120195488A1 (en) * 2009-05-29 2012-08-02 University Of Utah Research Foundation Methods and Compositions Related to Cellular Assays
US20110217701A1 (en) * 2010-03-03 2011-09-08 Carter Scott L Prognostic Marker for Endometrial Carcinoma
AU2011239707A1 (en) * 2010-04-13 2012-11-08 The Trustees Of Columbia University In The City Of New York Biomarkers based on a multi-cancer invasion-associated mechanism
EP2426216A1 (en) * 2010-09-01 2012-03-07 Institut Gustave Roussy (IGR) Prognostic and/or predictive biomarkers and biological applications thereof
ES2562274T3 (es) 2010-10-06 2016-03-03 Fundació Institut De Recerca Biomèdica (Irb Barcelona) Procedimiento para el diagnóstico, pronóstico y tratamiento de metástasis de cáncer de mama
JP5866669B2 (ja) 2010-10-26 2016-02-17 国立大学法人山口大学 乳がん発症感受性の判定方法
WO2012066093A1 (en) * 2010-11-19 2012-05-24 Santaris Pharma A/S Compounds for the modulation of pdz-binding kinase (pbk) expression
WO2012092529A2 (en) * 2010-12-29 2012-07-05 Expression Pathology, Inc. Protein biomarkers of recurrent breast cancer
CN102312002A (zh) * 2011-09-20 2012-01-11 李艳 一种快速检测BRCA1基因mRNA表达量的试剂盒
US9145559B2 (en) 2011-10-27 2015-09-29 Yeda Research And Development Co. Ltd. Methods of treating cancer
RU2633503C2 (ru) * 2011-10-28 2017-10-12 Онкотерапи Сайенс, Инк. Пептиды торк и содержащие их вакцины
EP2650682A1 (en) 2012-04-09 2013-10-16 Fundació Privada Institut de Recerca Biomèdica Method for the prognosis and treatment of cancer metastasis
RU2619739C2 (ru) * 2012-05-30 2017-05-17 Федеральное государственное бюджетное учреждение "Российский научный центр рентгенорадиологии" Министерства здравоохранения российской федерации (ФГБУ "РНЦРР" Минздрава России) Способ диагностики и прогноза при гиперпролиферативных заболеваниях молочной железы
EP2872532A4 (en) 2012-07-10 2016-04-13 Oncotherapy Science Inc CDCA1-EPITOPPEPTIDES FOR TH1 CELLS AND VACCINES THEREWITH
JP6283861B2 (ja) 2012-09-11 2018-02-28 オンコセラピー・サイエンス株式会社 Ｕｂｅ２ｔペプチドおよびそれを含むワクチン
US11306360B2 (en) * 2012-12-26 2022-04-19 Koninklijke Philips N.V. Assessment of cellular signaling pathway activity using linear combination(s) of target gene expressions
TWI658049B (zh) 2013-03-12 2019-05-01 腫瘤療法 科學股份有限公司 Ｋｎｔｃ２胜肽及含此胜肽之疫苗
EP3524698A1 (en) * 2013-10-09 2019-08-14 Fundació Institut de Recerca Biomèdica IRB (Barcelona) Method for the prognosis and treatment of cancer metastasis
JP2017512493A (ja) * 2014-03-14 2017-05-25 ブライアン ジェイ ツェルニキＣＺＥＲＮＩＥＣＫＩ， Ｂｒｉａｎ， Ｊ． 癌のｃｄ４＋ｔヘルパー１型応答の監視方法および免疫回復
JP6700512B2 (ja) 2014-08-04 2020-05-27 オンコセラピー・サイエンス株式会社 Ｃｄｃａ１由来ペプチドおよびそれを含むワクチン
US10380834B2 (en) 2015-07-22 2019-08-13 Mark A. Litman Replaceable flexible electronic table top with display function for gaming tables
US10311681B2 (en) 2015-08-19 2019-06-04 Mark A. Litman Electronic table game platform with secondary random event displays
SG11201802881YA (en) 2015-10-08 2018-05-30 Oncotherapy Science Inc Foxm1-derived peptide, and vaccine including same
US11609427B2 (en) 2015-10-16 2023-03-21 Ostendo Technologies, Inc. Dual-mode augmented/virtual reality (AR/VR) near-eye wearable displays
US11106273B2 (en) * 2015-10-30 2021-08-31 Ostendo Technologies, Inc. System and methods for on-body gestural interfaces and projection displays
KR102475128B1 (ko) 2015-11-30 2022-12-07 (주)아모레퍼시픽 Entpd4 억제를 통한 흑색종 예방 또는 치료제, 및 그 스크리닝 방법
KR102541256B1 (ko) 2015-11-30 2023-06-12 (주)아모레퍼시픽 Lipa 억제를 통한 흑색종 예방 또는 치료제, 및 그 스크리닝 방법
US10345594B2 (en) 2015-12-18 2019-07-09 Ostendo Technologies, Inc. Systems and methods for augmented near-eye wearable displays
US10578882B2 (en) 2015-12-28 2020-03-03 Ostendo Technologies, Inc. Non-telecentric emissive micro-pixel array light modulators and methods of fabrication thereof
US10353203B2 (en) 2016-04-05 2019-07-16 Ostendo Technologies, Inc. Augmented/virtual reality near-eye displays with edge imaging lens comprising a plurality of display devices
US10453431B2 (en) 2016-04-28 2019-10-22 Ostendo Technologies, Inc. Integrated near-far light field display systems
US10522106B2 (en) 2016-05-05 2019-12-31 Ostendo Technologies, Inc. Methods and apparatus for active transparency modulation
CA3025264A1 (en) 2016-05-25 2017-11-30 Inbiomotion S.L. Therapeutic treatment of breast cancer based on c-maf status
ES2874230T3 (es) * 2016-06-03 2021-11-04 Univ Kyushu Nat Univ Corp Proteína de fusión para mejorar la expresión de proteínas a partir de ARNm diana
EP3529387A4 (en) 2016-10-19 2020-06-10 The University of British Columbia PROCESS FOR LEACHING METAL SULPHIDES USING REAGENTS HAVING THIOCARBONYL FUNCTIONAL GROUPS
EP3548035A4 (en) 2016-11-30 2020-07-22 Case Western Reserve University COMBINATIONS OF 15-PGDH INHIBITORS WITH CORCOSTEROIDS AND / OR TNF INHIBITORS AND THEIR USES
CN110573154A (zh) 2017-02-06 2019-12-13 卡斯西部储备大学 调节短链脱氢酶活性的组合物和方法
KR102091747B1 (ko) * 2017-11-15 2020-03-20 주식회사 프로탄바이오 유방암 진단용 바이오마커 및 이의 용도
CA3082728A1 (en) 2017-11-22 2019-05-31 Inbiomotion S.L. Therapeutic treatment of breast cancer based on c-maf status
CN108441559B (zh) * 2018-02-27 2021-01-05 海门善准生物科技有限公司 一种免疫相关基因群作为标志物在制备评估高增殖性乳腺癌远处转移风险的产品中的应用
TW202023581A (zh) 2018-08-02 2020-07-01 日商腫瘤療法 科學股份有限公司 來自cdca1的胜肽及含有此的疫苗
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
CN109234384A (zh) * 2018-10-31 2019-01-18 中国医学科学院阜外医院 Hmgcl作为诊断标志物和治疗靶点在致密化不全型心肌病的应用
CN113748215B (zh) * 2018-11-04 2024-07-23 Pfs基因组学公司 用于乳腺癌的预后和预测来自辅助放射疗法的益处的方法和基因组分类器
WO2020106998A1 (en) 2018-11-21 2020-05-28 Case Western Reserve University Compositions and methods of modulating short-chain dehydrogenase activity
CN109811059B (zh) * 2019-03-31 2021-10-19 青岛泱深生物医药有限公司 生物标志物uggt1在宫颈疾病中的应用
AU2021224268A1 (en) 2020-02-21 2022-09-15 Case Western Reserve University Compositions and methods for treating renal injury
US20230332232A1 (en) * 2020-09-14 2023-10-19 Duke University Compositions and methods for diagnosing and treating a dystonia
AU2021345381A1 (en) 2020-09-18 2023-05-04 Jetti Resources, Llc Extracting base metals using a wetting agent and a thiocarbonyl functional group reagent
CN113025720B (zh) * 2021-04-28 2022-12-27 深圳市人民医院 一种用于检测原发性乳腺弥漫性大b细胞淋巴瘤的标志物及其试剂盒和应用
CN113466447B (zh) * 2021-05-28 2024-03-08 天津市肿瘤医院（天津医科大学肿瘤医院） 诊断胰腺癌预后的肿瘤标志物bzw1及检测试剂盒
CN114931665B (zh) * 2021-12-14 2024-09-27 广州医科大学 六型胶原α2亚基在神经修复产品中的应用
CN114334147B (zh) * 2021-12-24 2026-07-03 广东省人民医院 组合的stat信号通路相关基因在结直肠癌预后模型中的应用
CN114561358B (zh) * 2022-03-09 2023-10-03 广州源井生物科技有限公司 一种提高细胞慢病毒感染率的增强感染培养基及方法
CN114561470B (zh) * 2022-03-19 2024-03-01 新乡医学院 三阴性乳腺癌分子标志物及其应用
CN115616214B (zh) * 2022-09-20 2026-03-03 湖南中医药大学 Sox10抗体的应用、试剂盒
US12340627B2 (en) 2022-09-26 2025-06-24 Pison Technology, Inc. System and methods for gesture inference using computer vision
US12366920B2 (en) 2022-09-26 2025-07-22 Pison Technology, Inc. Systems and methods for gesture inference using transformations
US12366923B2 (en) 2022-09-26 2025-07-22 Pison Technology, Inc. Systems and methods for gesture inference using ML model selection
US12502110B2 (en) 2023-10-24 2025-12-23 Pison Technology, Inc. Systems and methods for determining physiological state based on surface biopotentials
CN118243927A (zh) * 2024-04-29 2024-06-25 东莞市石碣医院 eIF3b作为乳腺癌耐药检测靶点的应用
CN119007982A (zh) * 2024-07-26 2024-11-22 大连医科大学附属第二医院 基于肿瘤浸润边缘e-tls预测非小细胞肺癌预后的方法和设备
CN119955854B (zh) * 2025-01-20 2025-09-09 中国人民解放军军事科学院军事医学研究院 一种侏儒症小鼠模型的构建方法及应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1211279A (zh) * 1996-01-10 1999-03-17 科里克萨有限公司 用于治疗和诊断乳腺癌的组合物和方法
US6365358B1 (en) * 1997-12-12 2002-04-02 Incyte Genomics, Inc. Ubiquitin-like conjugating protein

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5744101A (en) 1989-06-07 1998-04-28 Affymax Technologies N.V. Photolabile nucleoside protecting groups
AR031250A1 (es) * 2000-07-11 2003-09-17 Corixa Corp Composiciones y metodos para la terapia y el diagnostico del cancer de pulmon
AU2001296448A1 (en) * 2000-10-03 2002-04-15 Curagen Corporation Tumor marker and methods of use
US20030157544A1 (en) * 2000-10-30 2003-08-21 Eos Biotechnology, Inc. Novel methods of diagnosing breast cancer, compositions, and methods of screening for breast cancer modulators
US20030104418A1 (en) * 2001-04-27 2003-06-05 Chao Zhang Diagnostic markers for breast cancer
US7189507B2 (en) * 2001-06-18 2007-03-13 Pdl Biopharma, Inc. Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer
CN1703522A (zh) 2002-09-30 2005-11-30 肿瘤疗法科学股份有限公司 诊断睾丸精原细胞瘤的方法
US7998695B2 (en) 2005-02-10 2011-08-16 Oncotherapy Science, Inc. Method of diagnosing bladder cancer
JP5339291B2 (ja) 2006-08-10 2013-11-13 オンコセラピー・サイエンス株式会社 乳癌に関連する遺伝子およびポリペプチド
TW200908998A (en) * 2007-06-27 2009-03-01 Oncotherapy Science Inc Compositions and methods of treating cancer

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1211279A (zh) * 1996-01-10 1999-03-17 科里克萨有限公司 用于治疗和诊断乳腺癌的组合物和方法
US6365358B1 (en) * 1997-12-12 2002-04-02 Incyte Genomics, Inc. Ubiquitin-like conjugating protein

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
LIPKOWITZ S,et al.The role of the ubiquitination-proteasome pathway in breast cancer. Ubiquitin mediated degradation of growth factor receptors in the pathogenesis and treatment of cancer.《BREAST CANCER RESEARCH》.2002,第5卷(第1期),8-15. *
ORLOWSKI ROBERT Z,et al.The role of the ubiquitination-proteasome pathway in breast cancer:applying drugs that affect the ubiquitin-proteasome pathway to the therapy of breast cancer.《BREAST CANCER RESEARCH》.2002,第5卷(第1期),1-7. *

Also Published As

Publication number Publication date
US20070269432A1 (en) 2007-11-22
US20120010090A1 (en) 2012-01-12
US8044193B2 (en) 2011-10-25
EP1668156B1 (en) 2011-05-04
ATE508202T1 (de) 2011-05-15
JP4620670B2 (ja) 2011-01-26
EP1668354A2 (en) 2006-06-14
ES2365732T3 (es) 2011-10-10
US7531300B2 (en) 2009-05-12
WO2005029067A3 (en) 2005-08-18
US20090286856A1 (en) 2009-11-19
JP2008092949A (ja) 2008-04-24
CN1890381A (zh) 2007-01-03
CN1898563A (zh) 2007-01-17
EP1668156A2 (en) 2006-06-14
WO2005028676A2 (en) 2005-03-31
JP2007506426A (ja) 2007-03-22
EP1668156B9 (en) 2012-02-22
TW200521243A (en) 2005-07-01
TW200512298A (en) 2005-04-01
DE602004032556D1 (enExample) 2011-06-16
JP2007506424A (ja) 2007-03-22
CN1890381B (zh) 2011-06-22
WO2005029067A2 (en) 2005-03-31
WO2005028676A3 (en) 2005-09-15
JP4579246B2 (ja) 2010-11-10

Similar Documents

Publication Publication Date Title
JP4579246B2 (ja) 乳癌を診断する方法
CA2500472A1 (en) Genes and polypeptides relating to human pancreatic cancers
CN101175862A (zh) 诊断膀胱癌的方法
US8029981B2 (en) Hypoxia-inducible protein 2 (HIG2), a diagnostic marker for clear cell renal cell carcinoma
JP2006500946A (ja) 精巣精上皮腫の診断方法
KR20050067409A (ko) 전립선암에 관련된 유전자 및 폴리펩티드
EP1537417A2 (en) Method of diagnosing colon and gastric cancers
US20070202109A1 (en) Method Of Diagnosing Breast Cancer
EP1786925B1 (en) Genes and polypeptides relating to breast cancers
KR20080040738A (ko) 대장암 관련 유전자 ｔｏｍ３４
CN101278060B (zh) 作为乳腺癌标志的基因galnt6和针对基因galnt6的小干扰rna
US20090220512A1 (en) Genes and polypeptides relating to prostate cancers
CN101273145A (zh) 癌症相关基因rasgef1a

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20111123

Termination date: 20120810